Renexxion - Ireland
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Regulatory Developments
  • Knowledge Centre
    • Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
    • Gastroparesis
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
  • News
    • Press >
      • Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
      • Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
      • Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
      • Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
  • Contact

​Gastrointestinal Dysmotility in Cystic Fibrosis (CF)

As of 2021, there are 32,100 people with CF recorded on the CF Foundation Registry. Gastrointestinal Dysmotility affects nearly all people with CF and has a significant impact on quality of life. Current management options are limited and there are no other therapies in development. There is therefore a large unmet need for an effective pan-GI prokinetic for people with CF. Renexxion aim to commence clinical trials in the US this year.

"CF has come full circle - CF was initially a gastrointestinal disease, then after treatments for pancreatic exocrine insufficiently improved, it became a respiratory condition, and now, as the pulmonary treatments are improving,
​gut disease has once  again come into focus
."


Review: Ng C., Prayle, A.P. Gastrointestinal Complications of cystic fibrosis.
​Paediatrics and Child Health, 2020, 30(10): 345-349.
Privacy Policy & Terms of Use
Copyright RENEXXION IRELAND LTD  2023.  All rights reserved.
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Regulatory Developments
  • Knowledge Centre
    • Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
    • Gastroparesis
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
  • News
    • Press >
      • Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
      • Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
      • Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
      • Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
  • Contact